Vertex Pharmaceuticals and bluebird bio have entered into an agreement with CMS to participate in a new Medicaid payment ...

Vertex Pharmaceuticals Inc. and bluebird bio Inc. — are the first to take part in a new Medicaid model intended to expand ...

Bluebird bio (BLUE) and Vertex (VRTX) have entered into outcome-based agreements with CMS aimed at expanding patient access ...

The Centers for Medicare & Medicaid Services said on Wednesday it had entered into agreements with Vertex Pharmaceuticals and ...

SOMERVILLE, Mass., December 04, 2024--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio") today announced it has reached an agreement with the Center for Medicare and Medicaid Innovation to offer an ...

CMS launches an outcomes-based model to expand access to FDA-approved gene therapies for sickle cell disease, aiming to ...

bluebird bio (BLUE) announced it has reached an agreement with the Center for Medicare and Medicaid Innovation or CMMI to offer an outcomes-based agreement for LYFGENIA gene therapy under the Cell and ...

The Centers for Medicare & Medicaid Services Dec. 4 announced that drug manufacturers bluebird bio, inc. (manufacturer of ...

CMS has negotiated outcomes-based agreements for sickle cell gene therapies with the two companies on behalf of participating state Medicaid programs.

Gene therapies can be life-changing for people, but the high cost plus the burden of treatment remain barriers to access and ...

The scAtlasVAE model integrates scRNA-seq data to create a CD8+ T cell atlas, enhancing understanding of immune responses in ...

Researchers used mitochondrial gene editing to model genetic disorders in mice, revealing profound impacts on brain function, ...